Copy number gain at Xp22.31 includes complex duplication rearrangements and recurrent triplications.

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Room 604B, Houston, TX 77030, USA.
Human Molecular Genetics (Impact Factor: 6.68). 02/2011; 20(10):1975-88. DOI: 10.1093/hmg/ddr078
Source: PubMed

ABSTRACT Genomic instability is a feature of the human Xp22.31 region wherein deletions are associated with X-linked ichthyosis, mental retardation and attention deficit hyperactivity disorder. A putative homologous recombination hotspot motif is enriched in low copy repeats that mediate recurrent deletion at this locus. To date, few efforts have focused on copy number gain at Xp22.31. However, clinical testing revealed a high incidence of duplication of Xp22.31 in subjects ascertained and referred with neurobehavioral phenotypes. We systematically studied 61 unrelated subjects with rearrangements revealing gain in copy number, using multiple molecular assays. We detected not only the anticipated recurrent and simple nonrecurrent duplications, but also unexpectedly identified recurrent triplications and other complex rearrangements. Breakpoint analyses enabled us to surmise the mechanisms for many of these rearrangements. The clinical significance of the recurrent duplications and triplications were assessed using different approaches. We cannot find any evidence to support pathogenicity of the Xp22.31 duplication. However, our data suggest that the Xp22.31 duplication may serve as a risk factor for abnormal phenotypes. Our findings highlight the need for more robust Xp22.31 triplication detection in that such further gain may be more penetrant than the duplications. Our findings reveal the distribution of different mechanisms for genomic duplication rearrangements at a given locus, and provide insights into aspects of strand exchange events between paralogous sequences in the human genome.

Download full-text


Available from: John Belmont, Jul 13, 2015
  • Source
    • "Some genes influencing brain function were: RABG3GAP1, involved in the regulation of neurotransmitters and exocytosis of hormones; PDE4D, involved in various signal transduction pathways such as learning and memory; GFRA1, related to neuronal differentiation and survival; and SUF1, a growth factor regulator in early embryonic development . The interaction of different CNVs to modulate phenotypes supports theories such as the digenic/multifactorial model for neuropsychiatric diseases or the twohit model, in which some aberrations occur in combination with other genomic CNVs (Girirajan et al. 2010; Liu et al. 2011 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Deletions in the 2p16.3 region that includes the neurexin (NRXN1) gene are associated with intellectual disability and various psychiatric disorders, in par-ticular, autism and schizophrenia. We present three unrelated patients, two adults and one child, in whom we identified an intragenic 2p16.3 deletion within the NRXN1 gene using an oligonucleotide comparative genomic hybrid-ization array. The three patients presented dual diagnosis that consisted of mild intellectual disability and autism and bipolar disorder. Also, they all shared a dysmorphic phenotype characterized by a long face, deep set eyes, and promi-nent premaxilla. Genetic analysis of family members showed two inherited dele-tions. A comprehensive neuropsychological examination of the 2p16.3 deletion carriers revealed the same phenotype, characterized by anxiety disorder, border-line intelligence, and dysexecutive syndrome. The cognitive pattern of dysexecu-tive syndrome with poor working memory and reduced attention switching, mental flexibility, and verbal fluency was the same than those of the adult pro-bands. We suggest that in addition to intellectual disability and psychiatric dis-ease, NRXN1 deletion is a risk factor for a characteristic cognitive and dysmorphic profile. The new cognitive phenotype found in the 2p16.3 deletion carriers suggests that 2p16.3 deletions might have a wide variable expressivity instead of incomplete penetrance.
    08/2014; 2(6). DOI:10.1002/mgg3.105
  • Source
    • "In two of these prior studies where large cohorts of patients with developmental delay were analyzed via CGH, an Xp22.31 duplication prevalence of 0.37% and 0.289% was noted, in comparison to healthy controls that had Xp22.31 duplication prevalences of 0.15% and 0.41%, respectively [Li et al., 2010; Liu et al., 2011]. In contrast, a more recent cohort of patients with developmental delay showed a 0.4% prevalence of Xp22.31 duplication compared to 0/2055 in controls [Faletra et al., 2012]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Comparative genomic hybridization (CGH) arrays have significantly changed the approach to identifying genetic alterations causing intellectual disability and congenital anomalies. Several studies have described the microduplication of Xp22.31, involving the STS gene. In such reports characteristic features and pathogenicity of Xp22.31 duplications remains a subject of debate. Here we present a series of nine previously unreported individuals with Xp22.31 duplications, found through microarray analysis in the course of genetic workup for developmental delay, associated with a combination of talipes anomalies, seizures and/or feeding difficulties. The size of the Xp22.31 duplications ranged from 294 kb to 1.6 Mb. We show a comparison of the breakpoints, inheritance and clinical phenotype, and a review of the literature. This clinically detailed series of Xp22.31 duplication patients provides evidence that the Xp22.31 duplication contributes to a common phenotype. © 2014 Wiley Periodicals, Inc.
    American Journal of Medical Genetics Part A 08/2014; 164A(8). DOI:10.1002/ajmg.a.36598 · 2.05 Impact Factor
  • Source
    • "For the majority of mutational signatures, however, we have limited insights into their etiology, resulting in a proliferation of neologisms that describe their genomic manifestations rather than the underlying (and unknown) mechanisms. These include ''kataegis'': referring to a processive clustering of cytosine mutations in a TpC context often near genomic rearrangements, thought to be caused by DNA-editing enzymes (Nik-Zainal et al. 2012a,b; Roberts et al. 2012, 2013; Burns et al. 2013; Taylor et al. 2013); ''chromoplexy'': balanced chains of rearrangements across multiple chromosomes in prostate cancer (Baca et al. 2013); ''chromothripsis'': clusters of tens to hundreds of localized genomic rearrangements occurring in a single catastrophic event in 2%–3% of all cancers (Stephens et al. 2011); and ''chromoanasynthesis'': a phenomenon occurring in the germline, driving localized gains and losses of chromosomal material through a replication-based mechanism (Liu et al. 2011a,b). Experimental model systems such as yeast and Caenorhabditis elegans have a tradition in the study of mutational processes, due to their convenient life cycles, compact genome, and ease of genetic manipulation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutation is associated with developmental and hereditary disorders, aging and cancer. While we understand some mutational processes operative in human disease, most remain mysterious. We used C. elegans whole genome sequencing to model mutational signatures, analyzing 183 worm populations across 17 DNA repair-deficient backgrounds, propagated for 20 generations or exposed to carcinogens. The baseline mutation rate in C. elegans was ~1/genome/generation, not overtly altered across several DNA repair deficiencies over 20 generations. Telomere erosion led to complex chromosomal rearrangements initiated by breakage-fusion-bridge cycles and completed by simultaneously acquired, localized clusters of breakpoints. Aflatoxin-B1 induced substitutions of guanines in GpC context, as observed in aflatoxin-induced liver cancers. Mutational burden increased with impaired nucleotide excision repair. Cisplatin and mechlorethamine, DNA crosslinking agents, caused dose- and genotype-dependent signatures among indels, substitutions and rearrangements. Strikingly, both agents induced clustered rearrangements resembling 'chromoanasynthesis,' a replication-based mutational signature seen in constitutional genomic disorders, suggesting interstrand crosslinks may play a pathogenic role in such events. Cisplatin mutagenicity was most pronounced in xpf-1 mutants, suggesting this gene critically protects cells against platinum chemotherapy. Thus, experimental model systems combined with genome sequencing can recapture and mechanistically explain mutational signatures associated with human disease.
    Genome Research 07/2014; 24(10). DOI:10.1101/gr.175547.114 · 13.85 Impact Factor
Show more